A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer

Summary

A single patient compassionate use clinical trial for the use of MBM-02 (TEMPOL) for the treatment of prostate cancer. The single patient will be exposed to orally administered TEMPOL for up to 12 months at a maximum total daily dose of 800mg.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications